NEW CHIEF OF STAFF AND NATIONAL DIRECTOR OF DEVELOPMENT
Kent Mora and Nancy Young Bring Experience in Organizational Leadership and Strategic Fundraising to Rare Disease Nonprofit
Newport Beach, Calif. – April 6, 2022 – CureDuchenne, a leading global nonprofit focused on finding and funding a cure for Duchenne Muscular Dystrophy (DMD), today announced the addition of its newest key leaders: Kent Mora as Chief of Staff and Nancy Young, MPA, CFRE as National Director of Development. The appointment of these two executives to the organization’s leadership team exemplifies CureDuchenne’s steady growth and its commitment to building the infrastructure to advance research and support for young people (and their families) fighting this rare disease.
Kent Mora is a senior-level marketing and finance expert with more than 20 years of experience and a track record of using data-driven, innovative and entrepreneurial approaches in the mentoring and management of his teams. Mora joins CureDuchenne as Chief of Staff during a time of organizational growth and brings vast experience in strategic development, program management and interdepartmental engagement from numerous executive-level positions.
Throughout his career, Mora has excelled in direct-to-consumer campaigns on behalf of leading companies, including Gwynnie Bee, Tracy Anderson, Hoover, Dirt Devil, Omaha Steaks, Gibson Brands, Breville, Vonage, and Schwan’s Home Services. He earned his Bachelor of Arts degree in Economics and Business from Westmont College.
Nancy Young is an award-winning fundraising professional with extensive experience in strategic planning, and program and policy development across varied fields, including healthcare, education and the arts. Her status as a Certified Fundraising Executive (CFRE) makes her uniquely qualified to lead CureDuchenne’s philanthropic efforts. She earned her Master of Public Administration from Columbia University’s School of International and Public Affairs (SIPA) a Master of Arts in Asian Studies with emphasis on Business and History, and Bachelor of Arts degree in English from UC Berkeley
Over her 30-year career, Young has helped raise more than $65M at the organizations she has served, including UCI Health’s Departments of Neurosciences and Geriatrics, Long Beach Public Library Foundation, Marymount California University and Yerba Buena Center for the Arts (SF). She was a development consultant with the national Australia Council for the Arts and other State and Local arts funding agencies in Australia for 13 years, a Program Officer with the Walter & Elise Haas Fund, and Assistant Program Director at the San Francisco Chamber of Commerce. She also published an award-winning novel in 2013.
“We are so fortunate to welcome Kent and Nancy to the CureDuchenne team and have entrusted them with two very important leadership positions,” said founder and CEO Debra Miller. “Kent brings with him the seasoned experience in marketing, finance and operations required to be our Chief of Staff and Nancy is the perfect fit to oversee our fundraising efforts with her deep understanding of strategic development and donor stewardship and her many years of successful campaigns. These additions to our leadership team will be critical to our mission as we work to improve and extend the lives of those living with Duchenne.”
CureDuchenne was founded by Paul and Debra Miller in 2003 after their son was diagnosed with the disease. The organization combines fundraising and venture philanthropy, leveraging donor dollars to maximize support for promising research into effective treatments for those suffering from Duchenne. They provide resources and guidance for families affected by the fatal genetic neuromuscular disorder and deliver the education and programs needed to support Duchenne patients and their families, caregivers and healthcare providers.
As the leading genetic killer of young boys, Duchenne affects more than 300,000 individuals worldwide. Those affected with Duchenne lose their ability to walk, feed themselves and breathe independently, and may succumb to heart failure.
CureDuchenne is recognized as a global leader in research, patient care and innovation for improving and extending the lives of those with Duchenne muscular dystrophy. CureDuchenne is dedicated to finding and funding a cure for Duchenne by breaking the traditional charitable mold through an innovative venture philanthropy model that funds groundbreaking research, early diagnosis and community education. For more information on how to help raise awareness and funds needed for research, please visit www.cureduchenne.org.